COR 001 - Corvidia Therapeutics

Drug Profile

COR 001 - Corvidia Therapeutics

Alternative Names: COR-001

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Corvidia Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cardiovascular disorders

Most Recent Events

  • 05 Apr 2017 University of Colorado and Corvidia Therapeutics initiate enrolment in a phase I pharmacokinetic and pharmacodynamic trial in patients with Renal failure and Inflammation in USA (NCT03126318)
  • 01 Aug 2016 Phase-I/II clinical trials in Cardiovascular disorders in USA (Parenteral) (NCT02868229)
  • 17 Feb 2016 Preclinical trials in Cardiovascular disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top